The primary outcome measure was severity of PTSD-symptoms (Harvard Trauma Questionnaire (HTQ)) and secondary outcome measures were depression and anxiety symptoms (Hopkins Symptom Checklist-25 (HSCL-25), Hamilton Depression and Anxiety rating scales (HAM-D, HAM-A)), somatisation (somatisation items of SCL-90 (SI-SCL-90)), quality of life (WHO-5-Well-being Index (WHO-5)) and functioning (Sheehan Disability Scale (SDS), Global Assessment of Functioning (GAF-F, GAF-S)).
Self-reported symptom severity was comparable among groups, but trends could be identified: SCL-90 results showed a prevalence of anxiety symptoms among depressors users, hostility or aggression in the tetrahydrocannabinol subgroup, and psychoticism in the stimulants subgroup.